1Mitchison DA. The action of antituberculosis drugs in shortcourse chemotherapy [J]. Tubercle. 1985,66(3) :219-225.
2Mitchison DA. Mechanisms of the action of drugs in the shortcourse chemotherapy [J]. Bull Int Union Tuberc. 1985,60 ( 1- 2) :36--40.
3World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008 [M]. Geneva.. World Health Organization, 2008(WHO/ HTM/TB/2008. 402).
4Global Alliance for TB Drug Development. Handbook of anti-tuberculosis agents[M]. Tuberculosis, 2008,88 : 85 170.
5Tomioka H, Namba K. Development of antituberculous drugs: current status and future prospects [J] Kekkaku. 2006, 81 (12) :753--774.
6Senol G, Erbaycu A,Ozsoz A. Incidence of cross resistance between rifampicin and rifabutin in Mycobacterium tuberculosis strains in Izmir, Turkey [J]. J Chernother, 2005,17 : 380-- 384.
7Lu PL,Peng CF, Hwang JJ,Chen YH. Activity of twelve secondline antimicrobial agents against Mycobacterium tuberculosis in Taiwan [J]. J Chemother,2008,20(2) :202--207.
8Moadebi S, Harder CK, Fitzgerald MJ, et al. Fluoroquinolones for the treatment of pulmonary tuberculosis [J]. Drugs, 2007, 67(14) :2077--2099.
9Agrawal D, Udwadia ZF, Rodriguez C, et al. Increasing incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai, India[J]. Int J Tuberc Lung Dis, 2009,1 (1) :79-83.
10P T, Chaiprasert A, Leechawengwongs M. In vitro activity of linezolid against multidrug-resistant tuberculosis(MDR-TB) and extensively drug-resistant (XDR)-TB isolates [J]. Int J Antimicrob Agents, 2009,33 (1): 190-- 191.
